ViewRay Inc falls on slashing full-year revenue outlook

Viewray

13/04/2023 12:31

** Radiation therapy system maker ViewRay Inc's  VRAY.O 
shares down 23.6% at $2.30 premarket
    ** Company cuts fiscal 2023 revenue forecast range to about
zero to 15% growth, from previous outlook of 25% to 40% growth
 urn:newsml:reuters.com:*:nTUABLWF3Z
    ** VRAY says its board has retained Goldman Sachs and Co LLC
as financial adviser for evaluation of strategic alternatives
    ** Company updates 2023 adj EBITDA outlook range to loss of
$75 mln to $85 mln vs previous forecast of loss of $70 mln to
$80 mln
    ** As of Wednesday's close, stock down ~33% this year

 (Reporting by Amna Karimi in Bengaluru)
 ((Amna.Karimi@thomsonreuters.com; +91 8083261226))